Clinical Trial

Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women

Study acronym: RSVVaccine
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 25, 2026 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Phase 1 study to evaluate safety, tolerability and immunogenicity a RSV vaccine in healthy women 18 to 49 years of age
Trial Details
NCT Number NCT07492706
Lead Sponsor MAXVAX Biotechnology Limited Liability Company
Conditions Respiratory Syncytial Virus (RSV)
Enrollment 120 participants
Start Date 2026-04-01
Primary Completion 2026-04-30 (estimated)
Study Completion 2027-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-03-25